NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-17-187 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.
Funding Opportunity PAR-17-189 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. The overall goals of the FOA are to improve the safety and effectiveness of current drugs for pediatric or obstetric patients, and to enhance the development of new drugs or a safer usage of the existing drugs for tailored therapies to meet emerging clinical needs for these special populations.
Notice NOT-OD-17-042 from the NIH Guide for Grants and Contracts
NIMHD Specialized Centers of Excellence for Research on Minority Health and Health Disparities (U54)
Funding Opportunity RFA-MD-17-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications to establish NIMHD Centers of Excellence in eligible institutions of higher education. The purpose of this initiative is to advance the science of minority health and health disparities by conducting transdisciplinary, multi-level research in a defined thematic area and by providing research opportunities and support for post-doctoral fellows, junior faculty, and other investigators.
Notice NOT-OH-17-008 from the NIH Guide for Grants and Contracts
Notice NOT-OH-17-009 from the NIH Guide for Grants and Contracts
Notice NOT-OH-17-010 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-036 from the NIH Guide for Grants and Contracts
Notice NOT-TR-17-012 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-FD-17-005 from the NIH Guide for Grants and Contracts. The intended outcome of this FOA is to advance efforts for a nationally integrated food safety system by assisting State manufactured food regulatory programs to achieve and maintain conformance with the Manufactured Food Regulatory Program Standards (MFRPS). The MFRPS are intended to ensure that State manufactured food regulatory programs develop, and maintain best practices for a high-quality regulatory program. Also, the program standards are intended to enhance food safety by establishing a uniform basis for measuring and improving the performance of manufactured food regulatory programs in the United States. Conformance with these program standards will help Federal and State programs better direct their regulatory activities at reducing hazards in firms that manufacture, process, pack, or hold foods. Grantees may also choose to pursue special projects that will further enhance the capacity of the State manufactured food regulatory program to protect public health and safeguard the food supply.
Notice NOT-TR-17-011 from the NIH Guide for Grants and Contracts
Notice NOT-GM-17-002 from the NIH Guide for Grants and Contracts
Notice NOT-EY-17-005 from the NIH Guide for Grants and Contracts
Notice NOT-EY-17-002 from the NIH Guide for Grants and Contracts
Notice NOT-EY-17-004 from the NIH Guide for Grants and Contracts
Notice NOT-EY-17-003 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-037 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-035 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-185 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.
Funding Opportunity PAR-17-186 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.